While smaller biotechnology companies are typically undertaking early stage research and perhaps even early clinical development in-house, the industry continues to see partnerships between big pharma and biotech in later stage development and commercialization. These collaborations are key to long-term success in the industry, as big pharma is able to provide capital and later-stage expertise and market access, while biotechnology companies are the crux of innovation. This session explores common legal and business issues at- stake in negotiating these collaborations or partnerships, such as:

• How to maintain control of and value in the biotechnology company’s platform or other technology while providing exclusivity to the partner
• How manufacturing gene and other cell therapies differs from traditional therapies and how this plays out in collaborations
• How does ownership of resulting intellectual property work if both parties are contributing to R&D